TR201807411T4 - DNA-PK inhibitörleri. - Google Patents
DNA-PK inhibitörleri. Download PDFInfo
- Publication number
- TR201807411T4 TR201807411T4 TR2018/07411T TR201807411T TR201807411T4 TR 201807411 T4 TR201807411 T4 TR 201807411T4 TR 2018/07411 T TR2018/07411 T TR 2018/07411T TR 201807411 T TR201807411 T TR 201807411T TR 201807411 T4 TR201807411 T4 TR 201807411T4
- Authority
- TR
- Turkey
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- cancer
- pharmaceutical composition
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 26
- 150000003839 salts Chemical class 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000011285 therapeutic regimen Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Abstract
Mevcut buluş, DNA-PK'nin inhibitörleri olarak faydalı olan bileşikler ile ilgilidir. Buluş aynı zamanda söz konusu bileşikleri içeren farmasötik olarak kabul edilebilir bileşimleri ve çeşitli hastalıkların, durumların ve bozuklukların tedavisinde bileşimlerin kullanılmasına yönelik yöntemleri sağlar.
Claims (4)
1. Bir bilesik olup, özelligi bilesigin asagidakilerden olusan gruptan: ve bunun farmasötik olarak kabul edilebilir tuzundan seçilmesidir.
2. Istem 1'e göre bir bilesik olup, özelligi bilesigin asagidaki gibi veya bunun farmasötik olarak kabul edilebilir bir tuzu olmasidir.
3. istem 1`e göre bir bilesik olup, özelligi bilesigin asagidaki gibi 10 veya bunun farmasötik olarak kabul edilebilir bir tuzu olmasidir.
4. Istem 1'e göre bir bilesik olup, özelligi bilesigin asagidaki gibi veya bunun farmasötik olarak kabul edilebilir bir tuzu olmasidir. istem 1`e göre bir bilesik olup, özelligi bilesigin asagidaki gibi veya bunun farmasötik olarak kabul edilebilir bir tuzu olmasidir. Farmasötik bir bilesim olup, özelligi istemler 1-5'ten herhangi birine göre bir bilesik veya bunun farmasötik olarak kabul edilebilir bir tuzunu ve farmasötik olarak kabul edilebilir bir eksipiyani içermesidir. Istemler 1-5'ten herhangi birine göre bir bilesik veya bunun farmasötik olarak kabul edilebilir bir tuzu veya farmasötik bir bilesimi olup, özelligi bir hücrenin bir DNA lezyonunu indükleyen bir ajana karsi duyarli hale getirilmesinde kullanima yönelik söz konusu bilesigi veya bunun farmasötik olarak kabul edilebilir bir tuzunu içermesidir. Istemler 1-5'ten herhangi birine göre bir bilesik veya bunun farmasötik olarak kabul edilebilir bir tuzu veya farmasötik bir bilesimi olup, özelligi bir hastada kanserin tedavi edilmesine yönelik terapötik bir rejimin güçlendirilmesinde kullanima yönelik söz konusu bilesigi veya bunun farmasötik olarak kabul edilebilir bir tuzunu içermesidir. istem 8'e göre kullanima yönelik söz konusu bilesigi veya bunun farmasötik olarak kabul edilebilir bir tuzunu içeren bir bilesik veya bunun farmasötik olarak kabul edilebilir bir tuzu veya farmasötik bir bilesim olup, özelligi terapötik rejimin radyasyon terapisini içermesidir. Istem 8,e göre kullanima yönelik söz konusu bilesigi veya bunun farmasötik olarak kabul edilebilir bir tuzunu içeren bir bilesik veya bunun farmasötik olarak kabul edilebilir bir tuzu veya farmasötik bir bilesim olup, özelligi terapötik rejimin anti-kanser kemoterapötik ajani içermesidir. Istemler 1-5'ten herhangi birine göre bir bilesik veya bunun farmasötik olarak kabul edilebilir bir tuzu veya farmasötik bir bilesimi olup, özelligi bir hastada kanserin tedavi edilmesinde kullanima yönelik söz konusu bilesigi veya bunun farmasötik olarak kabul edilebilir bir tuzunu içermesidir. Istem 8 veya 11'e göre kullanima yönelik söz konusu bilesigi veya bunun farmasötik olarak kabul edilebilir bir tuzunu içeren istemler 1-5'ten herhangi birine göre bilesik veya bunun farmasötik olarak kabul edilebilir bir tuzu veya farmasötik bir bilesim olup, özelligi kanserin gögüs kanseri, kolorektal kanser, gastroözofajeal kanser, fibrosarkom, glioblastom, hepatoselüler kanser, bas ve boyun kanseri, melanom, akciger kanseri, pankreas kanseri veya prostat kanseri olmasidir.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/056,560 US9376448B2 (en) | 2012-04-24 | 2013-10-17 | DNA-PK inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201807411T4 true TR201807411T4 (tr) | 2018-06-21 |
Family
ID=51932571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/07411T TR201807411T4 (tr) | 2013-10-17 | 2014-10-17 | DNA-PK inhibitörleri. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3057959B1 (tr) |
| JP (1) | JP6374959B2 (tr) |
| CN (1) | CN105636958B (tr) |
| AU (1) | AU2014337208B2 (tr) |
| BR (1) | BR112016008423B1 (tr) |
| CA (1) | CA2927392C (tr) |
| DK (1) | DK3057959T3 (tr) |
| ES (1) | ES2671354T3 (tr) |
| HR (1) | HRP20180804T1 (tr) |
| HU (1) | HUE037516T2 (tr) |
| LT (1) | LT3057959T (tr) |
| PL (1) | PL3057959T3 (tr) |
| PT (1) | PT3057959T (tr) |
| RS (1) | RS57306B1 (tr) |
| SI (1) | SI3057959T1 (tr) |
| TR (1) | TR201807411T4 (tr) |
| WO (1) | WO2015058031A1 (tr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2861566T3 (pl) | 2012-06-13 | 2017-06-30 | F.Hoffmann-La Roche Ag | Nowy diazaspirocykloalkan i azaspirocykloalkan |
| HUE045797T2 (hu) | 2012-09-25 | 2020-01-28 | Hoffmann La Roche | Hexahidropirrolo[3,4-c]pirrol-származékok és rokonvegyületek mint autotaxin (ATX) inhibitorok, valamint a lizofoszfatidsav (LPA) termelés inhibitorai, például vesebetegségek kezelésére |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| KR20160087900A (ko) | 2013-11-26 | 2016-07-22 | 에프. 호프만-라 로슈 아게 | 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일 |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| AU2016316717B2 (en) | 2015-09-04 | 2021-02-18 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| CA2991612A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| CR20180072A (es) | 2015-09-24 | 2018-02-26 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de atx |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| RU2018114289A (ru) | 2015-09-24 | 2019-10-24 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов аутотаксина (atx) |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| US11110108B2 (en) * | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
| SG11201908560SA (en) | 2017-03-16 | 2019-10-30 | Hoffmann La Roche | Heterocyclic compounds useful as dual atx/ca inhibitors |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| ES2896476T3 (es) * | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| CA3060597A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| EA039630B1 (ru) | 2017-05-18 | 2022-02-18 | Идорсия Фармасьютиклз Лтд | N-замещенные индольные производные |
| ES2929309T3 (es) | 2017-05-18 | 2022-11-28 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2 |
| JP2021503486A (ja) | 2017-11-20 | 2021-02-12 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物ならびに組成物および使用法 |
| CA3086925A1 (en) | 2018-01-05 | 2019-07-11 | Ichan School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| CA3093340A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| EP3906028A4 (en) * | 2018-12-31 | 2022-10-12 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
| CN112300126A (zh) * | 2019-07-31 | 2021-02-02 | 山东轩竹医药科技有限公司 | 杂环类dna-pk抑制剂 |
| CN112574211B (zh) * | 2019-09-29 | 2022-06-14 | 山东轩竹医药科技有限公司 | 杂环类激酶抑制剂 |
| CN112574179B (zh) * | 2019-09-29 | 2022-05-10 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
| JP7428806B2 (ja) * | 2019-12-31 | 2024-02-06 | 成都百裕制薬股▲ふん▼有限公司 | プリン誘導体および医薬におけるその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179912B2 (en) * | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| EP1678147B1 (en) * | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| US20090221581A1 (en) * | 2005-05-25 | 2009-09-03 | Philipp Wabnitz | Methods of treating pain |
| WO2008042639A1 (en) * | 2006-10-02 | 2008-04-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EA201201274A1 (ru) * | 2010-03-10 | 2013-04-30 | Инджениум Фармасьютиклз Гмбх | Ингибиторы протеинкиназ |
| CN106986863B (zh) * | 2012-04-24 | 2019-12-31 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
-
2014
- 2014-10-17 RS RS20180605A patent/RS57306B1/sr unknown
- 2014-10-17 JP JP2016523925A patent/JP6374959B2/ja active Active
- 2014-10-17 ES ES14800181.1T patent/ES2671354T3/es active Active
- 2014-10-17 CA CA2927392A patent/CA2927392C/en active Active
- 2014-10-17 EP EP14800181.1A patent/EP3057959B1/en active Active
- 2014-10-17 WO PCT/US2014/061033 patent/WO2015058031A1/en active Application Filing
- 2014-10-17 TR TR2018/07411T patent/TR201807411T4/tr unknown
- 2014-10-17 CN CN201480057118.6A patent/CN105636958B/zh active Active
- 2014-10-17 LT LTEP14800181.1T patent/LT3057959T/lt unknown
- 2014-10-17 PL PL14800181T patent/PL3057959T3/pl unknown
- 2014-10-17 AU AU2014337208A patent/AU2014337208B2/en active Active
- 2014-10-17 HU HUE14800181A patent/HUE037516T2/hu unknown
- 2014-10-17 DK DK14800181.1T patent/DK3057959T3/en active
- 2014-10-17 SI SI201430733T patent/SI3057959T1/en unknown
- 2014-10-17 PT PT148001811T patent/PT3057959T/pt unknown
- 2014-10-17 BR BR112016008423-3A patent/BR112016008423B1/pt active IP Right Grant
-
2018
- 2018-05-22 HR HRP20180804TT patent/HRP20180804T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3057959T1 (en) | 2018-07-31 |
| HUE037516T2 (hu) | 2018-09-28 |
| JP2016533366A (ja) | 2016-10-27 |
| EP3057959B1 (en) | 2018-02-28 |
| BR112016008423A2 (tr) | 2017-08-01 |
| RS57306B1 (sr) | 2018-08-31 |
| DK3057959T3 (en) | 2018-06-06 |
| CN105636958B (zh) | 2018-01-05 |
| PL3057959T3 (pl) | 2018-08-31 |
| ES2671354T3 (es) | 2018-06-06 |
| CA2927392C (en) | 2021-11-09 |
| CA2927392A1 (en) | 2015-04-23 |
| AU2014337208B2 (en) | 2018-05-24 |
| PT3057959T (pt) | 2018-06-04 |
| JP6374959B2 (ja) | 2018-08-15 |
| HRP20180804T1 (hr) | 2018-08-10 |
| EP3057959A1 (en) | 2016-08-24 |
| BR112016008423B1 (pt) | 2022-02-22 |
| WO2015058031A1 (en) | 2015-04-23 |
| CN105636958A (zh) | 2016-06-01 |
| LT3057959T (lt) | 2018-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| JP2016533366A5 (tr) | ||
| EA201590855A1 (ru) | Соединения пирролопиримидина как ингибиторы киназ | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| NZ729643A (en) | Combination therapy for treating cancer | |
| EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| NZ604480A (en) | Morpholino pyrimidines and their use in therapy | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| EA201791284A1 (ru) | Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| EA201591781A1 (ru) | Химические соединения | |
| EA201391286A1 (ru) | Лечение солидных опухолей | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| EA201171415A1 (ru) | Ингибиторы белков семейства iap | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний |